Targeting of epidermal growth factor receptor and protein kinase A: Molecular basis and therapeutic applications

Annals of Oncology

Volumn 11, Issue 7, 2000, Pages 777-783

  Tortora, G ^a   Ciardiello, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Cancer therapy; Growth factors; Protein kinase A

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

ANTINEOPLASTIC ACTIVITY; CANCER RESEARCH; CANCER THERAPY; ENZYME INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW;

CYCLIC AMP-DEPENDENT PROTEIN KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0033816198     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008390206250     Document Type: Review

References (73)

1. Epidermal growth factor-related peptides and their receptors in human malignancies
2. Protein modules and signalling networks
3. Specificity within the EGF family/ErbB receptor family signaling network
4. The EGF receptor as control transducer of heterologous signalling systems
5. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors
6. Altered gene expression in drug-resistant human breast cancer cells
7. cAMP-dependent protein kinase: Role in normal and malignant growth
8. Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase 3 activation in human ovarian cancer cells
9. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa
10. Tumor cyclic AMP binding proteins: An independent prognostic factor for disease recurrence and survival in breast cancer
11. Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: Correlations with clinicopathological features
12. The tissue-specific extinguisher locus TSE1 encodes a regulatory subunit of cAMP-dependent protein kinase
13. Molecular characterizatioon of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RIα of cyclic AMP-dependent protein kinase A
14. Protein kinase anchoring
15. Site-selective 8-chloroadenosine 3',5'monophosphate inhibits transformation and transforming growth factor α production in Ki-ras-transformed rat fibroblasts
16. 8-Cl-cAMP inhibits transforming growth factor α transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation
17. Down-regulation of RIαt subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes
18. Protein kinase I subunit-directed antisense inhibition of ovarian cancer cell growth: Crosstalk with tyrosine kinase signaling pathway
19. Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector
20. 8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor
21. The RIα subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells
22. Thyroid-stimulating hormone-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cyclic AMP-dependent protein kinase
23. Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex
24. Early events of human T lymphocyte activation are associated with type I protein kinase A activity
25. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor
26. Transmodulation of Epidermal Growth Factor Receptor function by cyclic AMP-dependent Protein Kinase
27. Therapeutic application of anti-growth factor receptor antibodies
28. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain
29. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein
30. Selective toxicity of TGF-α-PE40 to EGFR-positive cell lines: Selective protection of low EGFR-expressing cell lines by EGF
31. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors
32. Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα
33. 4,5-Bis(4-fluoroanilino)-phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity
34. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
35. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
36. Phase II study of anti-epidermal growth factor receptor (EGFr) antibody C225 alone in patients (pts) with metastatic renal cell carcinoma (RCC)
37. Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
38. A pharmacokinetic/pharmacodynamic trial od ZD1839 (Iressa(TM)), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor, in patients with five selected tumor types (a phase I-II trial of continous once-daily treatment)
39. Phase I study of oral ZD1839 (Iressa(TM)), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
40. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
41. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
42. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
43. Antitumor effects and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa(TM)), an EGFR-selective tyrosine kinase inhibitor
44. Efficacy of cytostatic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa(TM)), an inhibitor of EGFR receptor tyrosine kinase
45. 8-Cl-cAMP induces truncation and down-regulation of the RIα subunit and up-regulation of the RIIβ subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells
46. Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cAMP
47. 8-chloro-cAMP inhibits autocrine and angiogenic growth factors production in human colorectal and breast cancer
48. Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells
49. Phase I clinical study with 8-chloro-cAMP and evaluation of immunologic effects in cancer patients
50. Pharmakokinetics, metabolism and tumor disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice
51. Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: Toxicity, hormonal, and immunological effects
52. A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumors
53. Inhibition of the self-renewal capacity of blast progenitors from acute myeloblastic leukemia patients by site selective 8-chloro-cyclic adenosine 3',5' monophosphate (8-Cl-cAMP)
54. Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells
55. Synergistic interaction between paclitaxel and 8-Chloro-adenosine 3',5'-monophosphate in human ovarian carcinoma cell lines
56. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxy-nucleotide of cAMP-dependent protein kinase
57. An antisense oligodeoxy-nucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells
58. A single-injection protein kinase A-directed antisense treatment to inhibit turmour growth
59. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies
60. In vivo studies with antisense oligonucleotides
61. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotides targeting protein kinase A
62. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A
63. Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production
64. A Safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM 231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors
65. Cooperative anti-proliferative effects of 8-Cl-cAMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells
66. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A
67. Cooperative inhibition of renal cancer growth by anti-EGF receptor antibody and protein kinase A antisense oligonucleotide
68. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-EGFR-Receptor antibody on human breast cancer cell growth
69. Involvement of microtubules in the regulation of BCL-2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase
70. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A
71. Anticancer agents targeting signalling molecules and cancer cell environment: Challenges for drug development?
72. Epidermal growth factor receptor family and chemosensitization
73. Angiogenesis in cancer, vascular, rheumatoid and other disease